one example of a gene mutation’s link to cancer is theEGFR, or epidermal growth factor receptor, gene. EGFR mutations are often connected with non-small cell lung cancer (NSCLC). These are mutations that only occur in tumor cells; they are not usually mutations that can run in a family....
You may report side effects to FDA at 1-800-FDA-1088. You may report side effects related to AstraZeneca products. EGFR+ is epidermal growth factor receptor mutation-positive; NSCLC is non-small cell lung cancer. IMPORTANT SAFETY INFORMATION ...
ROS1 and EGFR are primary oncogenic drivers in non-small cell lung cancer (NSCLC) pathogenesis. However, EGFR mutations and ROS1 fusions are generally mutu... J Du,L Li,S Song,... - 《Journal of Cancer Therapy》 被引量: 0发表: 2024年 Triple positive lung cancer: A case report Back...
A letter to the editor is presented in response to the article related to the approach used for the second-line treatment of non-small-cell lung cancer with wild-type epidermal growth factor receptor (EGFR) by Ibrahim Elghissassi in the previous issue.Kim Anh Ma...
So, that I think is good. The hazard ratio, is it a home run? No. Is it incremental progress? Yes. I think the most important thing is we talk about immunotherapy. It’s great, but still in lung cancer, only for a quarter of the patients. What about the rest? This gave us a ...
Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.
HCC is not characterized by a unique driver mutation, as the case of EGFR mutations for lung cancer or K-Ras mutations for colorectal cancer, thus it is, at present, very difficult to identify a reliable target for antitumoral therapy. This review focuses on current translational research and...
[134]. AR-positive TNBC patients have lower survival rates than AR-negative ones [135]. Notably, even non-LAR TNBC cell lines showed involvement in AR signaling. AR was observed to up-regulate the EGFR ligand amphiregulin, promoting cell proliferation through the EGFR pathway, and the anti-...
In particular, cetuximab (chimeric IgG1 monoclonal antibody) binds epidermal growth factor (EGFR) and is used in RAS wild type metastatic CRC. It has been suggested that cetuximab, in addition to direct inhibition of EGFR, may act via ADCC. ADCC allows the antitumor innate immune response but...
Moreover, differentiation of thyroid cancer cells—as promoted by the expression of transcription factors—might be also influenced by microRNAs. For example, Let-7 microRNA family members are positive regulators of thyroid transcription factor-1. Multiple studies showed a marked decrease in the ...